D-Glutamic acid dimethyl ester hydrochloride (D-Glu(OMe)-OMe·HCl) is charged as the C-terminal amine component in solution-phase assembly of protected D-glutamyl dipeptide and tripeptide fragments intended for later-stage peptide active pharmaceutical ingredient synthesis. The hydrochloride salt is neutralized in situ with 1.05–1.15 mol equivalents of diisopropylethylamine per mole of HCl or with 2.05–2.15 mol equivalents of N-methylmorpholine, because residual HCl otherwise protonates the carbodiimide activator and reduces coupling efficiency. Coupling is executed in a jacketed 250 L glass-lined reactor equipped with a retreat-curve impeller and nitrogen overlay (99.999% N₂), using 1.0–1.1 mol equivalents of an N-protected amino acid pre-activated with 1.05–1.10 mol equivalents of HOBt monohydrate and 1.05–1.10 mol equivalents of EDC·HCl in dichloromethane:dimethylformamide 4:1 v/v at −5 °C to 0 °C. The batch is agitated at 80–100 rpm; completion is monitored by reversed-phase HPLC per USP <621> using a C18 column and an acetonitrile/0.1% phosphoric acid gradient. The protected dipeptide ester is isolated by extraction with water and tert-butyl methyl ether, washed with 5% w/v sodium bicarbonate, dried over sodium sulfate, and dried under vacuum at 35 °C for 12 h. Intermediate quality is controlled against ICH Q7 Section 7.3 and ICH Q6A decision tree #3; residual solvent limits under ICH Q3C Table 2 are applied as shown below.

Terminal products from this route are protected D-glutamyl dipeptide and tripeptide esters such as Fmoc-D-Xaa-D-Glu(OMe)-OMe and Boc-D-Xaa-D-Glu(OMe)-OMe, which are used as fragments in larger peptide APIs. The retained α- and γ-methyl esters permit orthogonal deprotection in later steps, while the D-configuration at the glutamyl residue provides resistance to peptidase degradation in the final peptide drug substance. Production-scale batches at 50–100 kg input show that phase separation at 25 °C is complete in 45–60 min; emulsion band formation is minimized by maintaining the dichloromethane/water ratio above 4:1 v/v during the first extraction.

Selective Alkaline Monohydrolysis and N-Protection for Solid-Phase Peptide Synthesis Synthons

For solid-phase peptide synthesis, the hydrochloride is converted into N-protected D-glutamic acid monomethyl ester building blocks through sequential N-acylation and partial saponification. In the acylation step, D-Glu(OMe)-OMe·HCl is dissolved in tetrahydrofuran:water 1:1 v/v and treated with 1.05–1.10 mol equivalents of Fmoc-OSu at pH 8.0–8.5, maintained by automatic pH-stat delivery of 10% w/v sodium carbonate at 0–5 °C. The N-protected dimethyl ester is extracted with ethyl acetate, washed with 0.1 M HCl and brine, and concentrated under vacuum below 40 °C. The residue is then subjected to partial saponification with 0.95–1.00 mol equivalent of sodium hydroxide in methanol at 0 °C for 3–5 h; the reaction is quenched by addition of 1 M HCl to pH 3.0–3.5. The desired monomethyl ester is separated from residual diester and diacid by silica gel column chromatography with dichloromethane:methanol 98:2 v/v. Published data for regioisomer ratios under these exact solvent and temperature conditions are limited; process development batches therefore require chiral HPLC-MS verification of the α- and γ-monomethyl ester ratio before scale-up.

Compliance controls for the resulting Fmoc-D-Glu(OMe)-OH synthon follow ICH Q7 Section 11.1 and USP <1503> for peptide synthesis building blocks. Acceptance criteria include HPLC purity ≥99.0%, enantiomeric excess ≥99.0%, residual Fmoc-OH ≤0.5%, residual starting material ≤0.5%, and loss on drying ≤0.5% per USP <731>. Because the α- and γ-methyl esters differ in acid lability, downstream solid-phase peptide synthesis protocols use 20% v/v piperidine in dimethylformamide for Fmoc deprotection and avoid prolonged exposure to trifluoroacetic acid until final cleavage. Terminal products are side-chain-protected D-glutamic acid building blocks used as coupling reagents in Fmoc/tBu solid-phase peptide synthesis of peptide APIs and research-grade peptides requiring a D-glutamyl residue with an orthogonal ester protection.

How Does Dimethyl Ester Hydrochloride Loading Affect Coupling Yield in Peptide-Drug Conjugate Linker Assembly?

In assembly of D-glutamate-based trifunctional linkers for peptide-drug conjugates, the hydrochloride is coupled to a carboxymethyl or PEG-acid spacer in dimethylformamide with 1.0–1.05 mol equivalents of D-Glu(OMe)-OMe·HCl relative to the spacer carboxylate, 1.10 mol equivalents of DIPEA, and 1.05 mol equivalents of HATU at 20–25 °C for 2–4 h. Coupling yield drops when the hydrochloride is charged below 0.95 mol equivalents because unconjugated spacer persists as a difficult-to-remove acidic impurity; charging above 1.10 mol equivalents increases residual free amine and produces symmetrical diamide byproducts detectable by LC-MS single-ion monitoring. The reaction is run in 20 L glass reactors with bottom-drain valves and in-line pH probes, and the batch is clarified through 0.45 μm PVDF filters before normal-phase or reversed-phase column purification. One methyl ester is then selectively hydrolyzed with lithium hydroxide in tetrahydrofuran:water 3:1 v/v at 0 °C for 2–4 h to yield the free carboxylate for subsequent conjugation to the peptide or antibody.

When these linker intermediates enter clinical manufacturing, quality controls align with ICH Q7 Sections 12 and 13, ICH Q3D elemental impurity risk assessments, and ICH Q3C residual solvent limits. Analytical release includes HPLC purity ≥98.0%, single unknown impurity ≤0.5%, and residual DMF ≤880 ppm in the isolated linker. Terminal products are D-glutamate-based bifunctional and trifunctional linkers conjugated to peptides or antibodies to yield peptide-drug conjugates and antibody-drug conjugates; the D-glutamyl α- and γ-carboxylates are used to attach payloads and solubilizing groups at independently controlled stoichiometric ratios.

Chiral pool synthesis converts D-glutamic acid dimethyl ester hydrochloride into N-acylated, cyclized, and ring-opened intermediates for small-molecule pharmaceutical candidates without loss of the D-stereochemical configuration. The hydrochloride is neutralized with 1.05–1.10 mol equivalents of triethylamine in dichloromethane at 0 °C, then treated with 1.0–1.2 mol equivalents of an acyl chloride or sulfonyl chloride at −5 °C to +5 °C for 4–8 h. The resultant N-protected dimethyl ester is cyclized in methanolic ammonia at 60–70 °C in a sealed pressure vessel to give D-pyroglutamic acid derivatives; ring-opening with primary amines in acetonitrile at 40–50 °C yields D-glutamic acid diamides and mixed amide-ester compounds. Each intermediate is purified by distillation under reduced pressure or by normal-phase chromatography, with stereochemical integrity checked by chiral HPLC per USP <621> using an amylose-based chiral column and hexane:ethanol mobile phases.

For regulatory starting material designation, manufacturers apply ICH Q11 Section 5.1 and assess potential mutagenic impurities under ICH M7 with a threshold of toxicological concern of 1.5 μg/day for clinical development. Residual solvent controls follow ICH Q3C Table 2, and heavy metal limits follow ICH Q3D based on the route of administration. Operational boundaries include pre-drying the hydrochloride at 40 °C under vacuum for 4 h when ambient relative humidity exceeds 60%, because water competes with the amine during acylation and lowers the yield of the N-acylated dimethyl ester. Terminal products are protected D-glutamic acid amides and D-pyroglutamic acid derivatives used as chiral intermediates in early-stage small-molecule candidate synthesis.

When Both Methyl Esters Must Remain Intact Through Multi-Step Downstream Processing

When D-glutamic acid dimethyl ester hydrochloride is used to assemble short D-amino acid-containing cosmetic peptide actives, both methyl esters are retained through the final peptide coupling step to maximize organic-solvent solubility and avoid premature gelation. The hydrochloride is neutralized with 1.0–1.1 mol equivalents of N-methylmorpholine in tetrahydrofuran at 0–5 °C, and the free amine is coupled to an N-acylated amino acid via mixed anhydride activation using 1.05 mol equivalents of isobutyl chloroformate at pH 7.8–8.2 for 30–45 min. The diester-protected peptide is washed with 5% w/v citric acid and 5% w/v sodium bicarbonate, then purified by normal-phase flash chromatography using ethyl acetate:hexane gradients to remove unreacted amino ester and acylated byproducts. Final ester deprotection is carried out by mild alkaline hydrolysis with 1 M sodium hydroxide in methanol at 0–5 °C, followed by lyophilization to yield the peptide active as a lyophilized powder.

For cosmetic application, the finished D-glutamyl peptide active is assessed under Regulation (EC) No 1223/2009 Annex I safety evaluation and manufactured under ISO 22716:2007; residual solvents in the cosmetic peptide concentrate are limited to 100 ppm for dichloromethane and 200 ppm for tetrahydrofuran when those solvents are used in the upstream synthetic route. In finished cosmetic formulations, the D-glutamyl peptide is typically incorporated at 0.001–0.05 wt%, depending on the sequence and available clinical safety data; the protected diester hydrochloride itself is not used directly in the formulation. Terminal products are synthetic D-glutamyl dipeptides and tripeptides used as stabilized peptide actives in topical cosmetic formulations, where the D-amino acid residue is intended to reduce peptidase susceptibility.